Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07389239 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Start date changed from estimate of Jun 23, 2026 to Sep 9, 2026
    • Interventions: Aldesleukin (Drug), Cyclophosphamide Conditioning (Drug), Decitabine (Drug), NY-ESO-1 TCR/ dnTGFβRII (Biological) to Aldesleukin (Drug), Cyclophosphamide Conditioning (Drug), Decitabine (Drug), NY-ESO-1 TCR/ dnTGFβRII (Biological)
    • Eligibility criteria expanded, about 63 words
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site details revised
  2. Primary endpoint revisedv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.
Trial Details
NCT Number NCT07389239
Lead Sponsor University of Chicago
Conditions
(from sponsor)		 Ovarian Cancer, Advanced Malignant Solid Tumor
Related terms Ovarian Neoplasms
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov